Trials / Completed
CompletedNCT00955799
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus
A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 455 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neramexane mesylate | Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day |
| DRUG | Placebo | Double-blind treatment period of 29 weeks placebo |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2009-08-10
- Last updated
- 2012-11-28
Locations
76 sites across 5 countries: United States, Austria, Brazil, Germany, Mexico
Source: ClinicalTrials.gov record NCT00955799. Inclusion in this directory is not an endorsement.